The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.

Fibrosis predicts post-surgical risk in aortic stenosis, reinforcing its role in guiding treatment decisions for both sexes.

Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treating heart valves, announced today the first commercial procedures with ShortCut™ - the world's first ...

Varanasi: A team of skilled doctors at the Cardiology department at the Institute of Medical Sciences (IMS), Banaras Hindu ...

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...

An experimental drug originally developed by Sanofi that is now being advanced by the Mayo Clinic significantly curbed ...

The collaboration aims to upskill over 300 cardiologists and radiologists in echocardiography and MRI, with a focus on ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.